EHS
EHS

Access to Treatment for Hepatitis B Virus Infection – Worldwide, 2016

Among persons living with HBV worldwide, approximately 27 million (10.5%) were aware of their infection, including 4.5 million (16.7%) who were on treatment. In 2017, all but two low- and middle-income countries could legally procure generic entecavir or tenofovir, the medicines active against HBV infection.
EHS
Back to top button